Summary:
The objective of this study is to evaluate the effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain.
Qualified Participants Must:
• Be 18 years or age or older
•
Have chronic low back pain ≥3 months in duration, Quebec Task Force in Spinal Disorders class 1 or 2, with documented history of previous inadequate treatment response to at least 3 different categories of agents commonly used and generally considered effective for the treatment of chronic low back pain
Qualified Participants May Receive:
Study-related medical care and investigational medication at no cost and may be compensated for time and travel.